iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Earnings data Q1 2023

Earnings data Q2 2023

AAON

MercadoLibre

Northeast Community Bancorp

MercadoLibre (MELI), iRadimed (IRMD), Northeast Community Bancorp (NECB) and AAON (AAON) have been selected as the top picks with a high net income ratio.

4 Best Profitable Stocks to Buy Banking on Net Income Ratio

WINTER SPRINGS, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi, President and Chief Executive Officer of the Company, will be presenting at the 35th Annual Roth Conference in Laguna Niguel, CA. Mr. Susi is scheduled for a live fireside chat on Monday, March 13, at 11:30 am PT.

IRADIMED CORPORATION To Present at the 35th Annual Roth Conference

Letter Notifying Customers of Potential Issues with MRidium 1057 MRI Syringe Adapter Set Letter Notifying Customers of Potential Issues with MRidium 1057 MRI Syringe Adapter Set

IRADIMED CORPORATION Issues Urgent Medical Device Correction

IRadimed came in with a strong set of Q4 and full-year numbers. We noted tremendous momentum on IRMD's profitability front, with strong incremental ROIC on small reinvestment for growth.

IRadimed: Revise To Buy With Exceptional Incremental ROIC In Q4

Revenues rose 25.2% YOY to $14.9 million, due to a rapid acceleration of Patient Monitors and Disposables sales, and a significant contribution from a new product launch. IRMD announced a special cash dividend of $1.05 per share, which is payable to shareholders of record at the close of business on February 13th, 2023.

IRadimed Q4: A Bottom-Line Beat, A Special Cash Dividend, Maintain Buy

IRadimed Corporation (NASDAQ:IRMD ) Q4 2022 Earnings Conference Call February 2, 2023 11:00 AM ET Company Participants Roger Susi - President & CEO Jack Glenn – CFO Conference Call Participants Scott Henry - ROTH Capital Operator Ladies and gentlemen, welcome to IRadimed Corporation Fourth Quarter and Full Year 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

IRadimed Corporation (IRMD) Q4 2022 Earnings Call Transcript

iRadimed (IRMD) delivered earnings and revenue surprises of 3.23% and 0.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

IRadimed (IRMD) Q4 Earnings Top Estimates

WINTER SPRINGS, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today its financial results for the fourth quarter and year ended December 31, 2022. The Company also announced that its Board of Directors approved a special cash dividend of $1.05 per share on the Company's outstanding common stock. This special cash dividend is payable on February 21, 2023, to shareholders of record at the close of business on February 13, 2023. The Company is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of a non-magnetic intravenous ("IV") infusion pump system and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

IRADIMED CORPORATION Announces Fourth Quarter and Full Year 2022 Financial Results and Announces Special Cash Dividend

WINTER SPRINGS, Fla., Jan. 26, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 fourth quarter financial results before the market opens on Thursday, February 2, 2023.  IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold 2022 Fourth Quarter Financial Results Conference Call on February 2nd

iRadimed (IRMD) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Growth Investors Will Love iRadimed (IRMD)

WINTER SPRINGS, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced selected preliminary financial results for the fourth quarter that ended December 31, 2022. Fourth-quarter revenue is expected to be approximately $14.9 million, up 25% from the prior year and above the Company's fourth-quarter guidance of $14.1 million - $14.8 million.

IRADIMED CORPORATION Announces Preliminary Financial Results for Fourth Quarter 2022

iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here is Why Growth Investors Should Buy iRadimed (IRMD) Now

Shockwave Medical

Tactile Systems

Here we discuss ShockWave Medical (SWAV), iRadimed (IRMD) and Tactile Systems Technology (TCMD), which have the potential to outperform their industry going forward.

3 Medical Instruments Stocks With Potential to Outperform

IRadimed Corporation continues to re-rate to the downside despite robust fundamentals last quarter. Despite this, the market may have discounted the stock correctly looking at revenue, EPS estimates in our opinion.

iRadimed: Reduce To Hold, Price Visibility Around $28 More Certain

IRadimed Corporation (NASDAQ:IRMD ) Q3 2022 Earnings Conference Call November 3, 2022 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - Chief Financial Officer Conference Call Participants Operator Welcome to the IRadimed Corporation Third Quarter 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

IRadimed Corporation (IRMD) CEO Roger Susi on Q3 2022 Results - Earnings Call Transcript

iRadimed (IRMD) delivered earnings and revenue surprises of 20.83% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

IRadimed (IRMD) Q3 Earnings and Revenues Top Estimates

WINTER SPRINGS, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2022. The Company is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of a non-magnetic intravenous ("IV") infusion pump system and non-magnetic patient vital signs monitoring systems designed for use during MRI procedures.

IRADIMED CORPORATION Announces Third Quarter 2022 Financial Results

Announces Preliminary Financial Results for Third Quarter 2022 Announces Preliminary Financial Results for Third Quarter 2022

IRADIMED CORPORATION Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA

WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent.

IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors

Doximity

Gilead Sciences

If you want to invest in profitable healthcare companies in this bear market, these all look like good bets.

3 Healthcare Stocks With High Profit Margins

IRadimed Corporation (NASDAQ:IRMD ) Q2 2022 Earnings Conference Call July 29, 2022 11:00 AM ET Company Participants Roger Susi – President and Chief Executive Officer Jack Glenn – Chief Financial Officer Conference Call Participants Scott Henry – ROTH Capital Partners Operator Welcome to the IRadimed Corporation Second Quarter 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

IRadimed Corporation (IRMD) CEO Roger Susi on Q2 2022 Results - Earnings Call Transcript

iRadimed (IRMD) delivered earnings and revenue surprises of 12.50% and 0.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IRadimed (IRMD) Beats Q2 Earnings and Revenue Estimates

WINTER SPRINGS, Fla., July 29, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today its financial results for the three and six months ended June 30, 2022. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

IRADIMED CORPORATION Announces Second Quarter 2022 Financial Results

WINTER SPRINGS, Fla., July 28, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market opens on Friday, July 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

UPDATE - IRADIMED CORPORATION to Hold 2022 Second Quarter Financial Results Conference Call on July 29th

WINTER SPRINGS, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market opens on Friday, July 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

News for iRadimed Stock (IRMD)